Neuland Laboratories Ltd. (BSE: 524558) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹25,274 Cr, it ranks #318 by market cap among the 6,137 Indian listed companies on FinBizNet, and #16 of 86 in Medicinal Chemicals and Botanical Products. At ₹18,865.00 (as of 25 Oct 2026), the share price is 22.1% below its 52-week high of ₹24,225.00 and 64.0% above its 52-week low of ₹11,500.00. The share price is up 16.5% over one year and up 1.7% over three months.
| Current Price | ₹18,865.00 |
|---|---|
| Market Cap | ₹25,274 Cr |
| BSE Code | 524558 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 67.7 |
| Return on Equity | 21.42% |
| Return on Assets | 11.94% |
| 52-Week Range | ₹11,500.00 – ₹24,225.00 |
| 1-Year Price Change | +16.5% |
| 3-Month Price Change | +1.7% |
| Beta (1Y) | 0.87 |
| Dividend Yield | 0.18% |
| Headquarters | Hyderabad, Telangana |
| Website | www.neulandlabs.com |
| Revenue | ₹642 Cr |
|---|---|
| Net Profit | ₹148 Cr |
| Net Margin | 23.0% |
| EPS (Basic) | ₹115.10 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Neuland Laboratories Limited engages in the manufacture and sale of active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
1. Segment Adjustment-This segment engages in the development, manufacture, and marketing of active pharmaceutical ingredients (APIs) for the generic market; and provision of custom manufacturing solutions to develop and manufacture APIs on an exclusive basis primarily for innovators. 2. Manufacture and Sale of Active Pharmaceutical Ingredients and Allied Services-0
1. Manufacture and Sale of Active Pharmaceutical Ingredients and Allied Services-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Neuland Laboratories Ltd. | ₹25,274 Cr | 67.7 | 21.42% | ₹642 Cr | +16.5% |
Listed by market capitalisation. Ratios are shown for context only.
Neuland Laboratories Ltd. is trading at ₹18,865.00, with a market capitalisation of ₹25,274 Cr.
Neuland Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Neuland Laboratories Ltd. has a P/E of 67.7 and a return on equity of 21.42%.
Neuland Laboratories Ltd. is listed on the BSE under the scrip code 524558.
Neuland Laboratories Ltd.'s share price is up 16.5% over one year and up 1.7% over three months. Its 52-week range is ₹11,500.00 to ₹24,225.00.
In Q1 FY27, Neuland Laboratories Ltd. reported revenue of ₹642 Cr and net profit of ₹148 Cr, with basic EPS of ₹115.1 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.